Friday, 24 May 2024


Bio-Techne announces new distribution agreement with Thermo Fisher

02 May 2024 | News

Partnership marks an important collaboration between two industry leaders in the fields of scientific research

image credit- shutterstock

image credit- shutterstock

Bio-Techne Corporation, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, has announced a significant milestone in its commitment to providing cutting-edge solutions to its customers.

Effective May 1, 2024, Bio-Techne has entered into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe.

This partnership marks an important collaboration between two industry leaders in the fields of scientific research, diagnostics, and biotechnology. Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, Immunoassay kits, reagents and enzymes to laboratories and research institutions across Europe.

According to Kim Kelderman, Bio-Techne's President and Chief Executive Officer, "By leveraging the Fisher Scientific Channel's extensive European distribution network and industry expertise, we aim to enhance support for researchers and accelerate scientific discoveries that address some of the most pressing challenges in healthcare today."

Bio-Techne's state-of-the-art products are designed to accelerate research and improve outcomes in areas including cell and gene therapy, immunology, neuroscience, and more. With this collaboration, Thermo Fisher reinforces its commitment to providing customers with access to the latest technologies and expertise, ultimately advancing scientific knowledge and improving human health.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account